Digital Diagnostics Inc. is a pioneering autonomous AI diagnostics company on a mission to benefit patients by transforming the accessibility, affordability, equity, and quality of global healthcare through the application of technology in the medical diagnosis and treatment process. To benefit patients by transforming the accessibility, affordability, equity, and quality of global healthcare through the application of technology in the medical diagnosis and treatment process. To be the world leader in developing safe, effective, and equitable AI platforms that improve patient outcomes. Digital Diagnostics is a leading AI diagnostic healthcare technology company on a mission to transform the quality, accessibility, and affordability of healthcare world-wide. Our AI systems are autonomous - not assistive - enabling disease detection in primary care that would typically involve specialists. Our algorithms are developed with insights from leading medical experts and are based on existing clinical practice guidelines. Our deep learning-based detectors search for the same signs of disease as a clinician, so we know how the AI came to its decision. IDx-DR is an AI diagnostic system that autonomously diagnoses patients for diabetic retinopathy (including macular edema). IDx-DR is modeled to look for and make decisions based on the same clinical disease detectors that eye care specialists would use. IDx-DR was validated against patient outcomes using a surrogate outcome standard to keep patient safety the main priority. In the pivotal clinical trial, IDx-DR referred 100% of patients with at least moderate diabetic retinopathy and more than 96% of patients with diabetic macular edema.